Jubilant Life Sciences announced that on 29 January 2021, its subsidiary, Jubilant Pharma redeemed the
principal amount of USD 100 million on pro-rata basis out of USD 300 million 4.875% Senior Notes due 2021 at a redemption price of 101.21875% together with the accrued interest till date. JPL had made the
first early redemption of USD 100 million in November 2019 and the outstanding amount of the
Notes after the redemption of 29 January 2021 is USD 100 million.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
